188 Results

People

  1. Gansbacher
    Gansbacher
  2. Welte
    Welte
  3. Dupont
    Dupont
  4. Kolitz
    Kolitz
  5. Fong
    Fong
  6. Mertelsmann
    Mertelsmann
  7. Stutman
    Stutman
  8. Fair
    Fair
  9. Gilboa
    Gilboa
  10. Heston
    Heston

Groups

  1. Department of Medicine (49)
  2. Sloan Kettering Institute Faculty (37)
  3. GSK Faculty (28)
  4. Solid Tumor Oncology Division (27)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  6. Hematologic Malignancies, Division of (18)
  7. Surgery (18)
  8. Center for Molecular Imaging and Biotechnology (16)
  9. Immunology Program Faculty (16)
  10. Center for Hematologic Malignancies (14)
  1. "interleukin-2"
Formats
  1. Journal Article (178)
  2. Meeting Abstract (5)
  3. Conference Paper (4)
  4. Review (1)
Groups
  1. Department of Medicine (49)
  2. Sloan Kettering Institute Faculty (37)
  3. GSK Faculty (28)
  4. Solid Tumor Oncology Division (27)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  6. Hematologic Malignancies, Division of (18)

More Groups

People
  1. Bernd Gansbacher (28)
  2. Karl Welte (22)
  3. Bo Dupont (12)
  4. Jonathan Kolitz (11)
  5. Osias Stutman (10)
  6. Roland Mertelsmann (10)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2017 (2)
  6. 2016 (1)

More Years

Publications
  1. Journal of Immunology (22)
  2. Cancer Research (13)
  3. Journal of Experimental Medicine (9)
  4. Cellular Immunology (8)
  5. Journal of Clinical Oncology (6)
  6. Cancer Gene Therapy (4)

More Publications

Publishers
  1. American Association for Cancer Research (22)
  2. The American Association of Immunologists, Inc (22)
  3. Elsevier Inc. (19)
  4. Nature Publishing Group (15)
  5. Springer (13)
  6. Lippincott Williams & Wilkins (10)

More Publishers

Results (188)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HSV-mediated production of IL-2-secreting hepatoma vaccines that confer specific immunity and protection against subsequent tumor challenge
    Conference Paper

    Weigel, T.; Federoff, H.; Brownlee, M.; Ng, B.; Tung, C.; Karpoff, H.; Brennan, M.; Fong, Y.
    American College of Surgeons (1995)

    Fulltext@MSK | Save
  • Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
    Journal Article

    Atzpodien, J.; Hänninen, E. L.; Kirchner, H.; Franzke, A.; Körfer, A.; Volkenandt, M.; Duensing, S.; Schomburg, A.; Chaitchik, S.; Poliwoda, H.
    European Journal of Cancer (1995)

    Fulltext@MSK | Save
  • Rejection of mouse melanoma elicited by local secretion of interleukin‐2: Implicating macrophages without T cells or natural killer cells in tumor rejection
    Journal Article

    Hara, I.; Nguyen, H.; Takechi, Y.; Gansbacher, B.; Chapman, P. B.; Houghton, A. N.
    International Journal of Cancer (1995)

    Fulltext@MSK | Save
  • The impact of gene therapy on T cell function in cancer
    Journal Article

    Zier, K. S.; Gansbacher, B.
    Human Gene Therapy (1995)

    Fulltext@MSK | Save
  • B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro
    Journal Article

    Salvadori, S.; Gansbacher, B.; Wernick, I.; Tirelli, S.; Zier, K.
    Human Gene Therapy (1995)

    Fulltext@MSK | Save
  • Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia
    Journal Article

    Caron, P. C.; Lai, L. T.; Scheinberg, D. A.
    Clinical Cancer Research (1995)

    Fulltext@MSK | Save
  • RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ
    Journal Article

    Tjuvajev, J.; Gansbacher, B.; Desai, R.; Beattie, B.; Kaplitt, M.; Matei, C.; Koutcher, J.; Gilboa, E.; Blasberg, R.
    Cancer Research (1995)

    Fulltext@MSK | Save
  • Phase III randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma
    Journal Article

    Law, T. M.; Motzer, R. J.; Mazumdar, M.; Sell, K. W.; Walther, P. J.; O'Connell, M.; Khan, A.; Vlamis, V.; Vogelzang, N. J.; Bajorin, D. F.
    Cancer (1995)

    Fulltext@MSK | Save
  • In vivo cytokine gene transfection of murine bladder cancer by retroviral packaging cell line
    Meeting Abstract

    Saito, S.; Heston, W. D.; Fair, W. R.; Gilboa, E.
    Proceedings of the American Association for Cancer Research Annual Meeting (1994)

    Fulltext@MSK | Save
  • Use of cytokine gene-modified prostatic tumor cells for the treatment of advanced prostate cancer
    Meeting Abstract

    Vieweg, J.; Heston, W. D. W.; Fair, W. R.; Gilboa, E.
    Journal of Urology (1994)

    Fulltext@MSK | Save